Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-TAIL 201 feasibility study of ABCP in advanced non-squamous NSCLC
jRCTs031200088Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Oct 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of atezolizumab, bevacizumab, carboplatin and paclitaxel in Non-small cell lung cancer (NS-NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: 6-month progression-free survival rate. Started Oct 2020; status: completed.
02
Drugs
atezolizumabbevacizumabcarboplatinpaclitaxel
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs031200088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031200088.